on-randomized, prospective, non-controlled study of changes of lipid parameters after introduction of evolocumab in patients with heterozygous familial hypercholesterolemia under LDL-apheresis therapy.
Not Applicable
- Conditions
- Homozygous familial hypercholesterolemia
- Registration Number
- JPRN-UMIN000022603
- Lead Sponsor
- Kanazawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2
Inclusion Criteria
Not provided
Exclusion Criteria
Myocardial infarction or unstable angina within 8 weeks Severe anemia (Hb <10g/dL) Allergy against evolocumab Immunosupressive therapy Severe hepatic disorder (ASTorALT>100IU/L) Severe renal disorder (BUN>40mg/dL or Cre>2.0mg/dL) (Possible of) pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of the time constant average levels of LDL-C and apoB before and after evolocumab thereapy.
- Secondary Outcome Measures
Name Time Method